Among the 7 new molecular entities marketed during this period only two have innovative potential. The first is finasteride, an inhibitor of 5-alfa-reductase which has been proven effective in reducing the size of prostate and related symptoms in men with prostatic hypertrophy. While the magnitude of its effects is probably negligible for patients with only modest symptoms, the drug may be of advantage in subjects with moderate or severe symptoms who are at risk for surgery or desire to postpone it. Anti-endotoxin monoclonal antibodies can reduce mortality when used soon in patients with septic shock from Gram-negative bacteria. Their use is limited by the difficulty to identify in due time the relatively limited subset of patients that can benefit from treatment and by their very high cost.
|Translated title of the contribution||New drugs on the market August-October 1992|
|Number of pages||6|
|Journal||Ricerca e Pratica|
|Publication status||Published - 1993|
ASJC Scopus subject areas